- $111.15m
- $109.71m
- $55.64m
- 47
- 25
- 97
- 57
Annual income statement for Exagen, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 42 | 48.3 | 45.6 | 52.5 | 55.6 |
| Cost of Revenue | |||||
| Gross Profit | 25.4 | 27.7 | 21.3 | 29.5 | 33.1 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 57.2 | 72.4 | 91.6 | 75.4 | 69.3 |
| Operating Profit | -15.2 | -24.1 | -46.1 | -22.8 | -13.6 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -16.8 | -26.7 | -47.7 | -23.7 | -15.1 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -16.7 | -26.9 | -47.4 | -23.7 | -15.1 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -16.7 | -26.9 | -47.4 | -23.7 | -15.1 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -16.7 | -26.9 | -47.4 | -23.7 | -15.1 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.32 | -1.68 | -2.56 | -1.4 | -0.83 |